OnKure Therapeutics (OKUR) Operating Income (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Operating Income for 7 consecutive years, with -$16.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income fell 3.52% year-over-year to -$16.9 million; the trailing twelve-month figure through Jun 2026 stood at -$62.1 million (up 2.2% YoY), and the FY2025 full-year result was -$63.0 million, down 15.75% from the prior year.
• Operating Income fell to -$16.9 million in Q2 2026 per OKUR's latest filing, from -$15.6 million in the prior quarter.
• Across five years, Operating Income topped out at $21.1 million in Q4 2023 and bottomed at -$21.0 million in Q2 2023.
• Historically, Operating Income has averaged -$13.4 million across 5 years, with a median of -$15.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Income soared 244.99% in 2023, then tumbled 188.57% in 2024.
• Over 5 years, Operating Income stood at -$14.6 million in 2022, then jumped by 244.99% to $21.1 million in 2023, then sank by 188.57% to -$18.7 million in 2024, then advanced by 24.46% to -$14.1 million in 2025, then dropped by 19.64% to -$16.9 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$16.9 million, -$15.6 million, and -$14.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.